News
-
September 05, 2018Industry executive adds considerable financial expertise as audit committee chairperson
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the appointment of Avery (Chip) W....
-
August 13, 2018
Recent Corporate Highlights: Closed initial public offering of common stock on July 19, 2018, generating $63.9 million in gross proceeds Expanded pipeline with two additional clinical-stage assets...
-
July 31, 2018- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the appointment of Mark Rigby, MD,...
-
July 19, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of its initial public...
-
May 09, 2018-- Provention acquires PRV-031 (teplizumab) and plans to initiate pivotal Phase 3 clinical trial to intercept early-onset type 1 diabetes, a pediatric orphan indication
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...